Chemotherapy: Open Access
Open Access

Kathleen M Fox

Publications

• Research Article
  Incidence and Predictors of Pulmonary Events among Patients with Hodgkin Lymphoma Treated with Bleomycin in the US Department of Defense Healthcare System
  Author(s): Kathleen M Fox, Joseph Feliciano, Carlos Alzola, Amber Evans and CDR Tod MorrisKathleen M Fox, Joseph Feliciano, Carlos Alzola, Amber Evans and CDR Tod Morris
  
  Objectives: Multi-agent chemotherapy including bleomycin, doxorubicin, dacarbazine, and vinblastine has been the standard of care for initial treatment of Hodgkin Lymphoma (HL) for over 40 y. The study objective was to estimate the rate of new pulmonary events in HL patients exposed to bleomycin. Methods: A retrospective cohort study supplemented by chart abstraction included newly diagnosed adult HL patients from the US DOD military healthcare system between 1/1/2005 and 12/31/2013 and followed until death, disenrollment on 6/30/2016. Patients with concurrent primary malignancies and those receiving <2 chemotherapy agents as first-line treatment were excluded. Pulmonary events (pulmonary fibrosis, pneumonitis, interstitial lung disease, pneumonia, bronchiolitis obliterans, acute respiratory distress syndrome) after exposure to bleomycin .. View More»
  DOI: 10.4172/2167-7700.1000261

  Abstract PDF

Relevant Topics